Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 70.60B | 64.97B | 60.23B | 58.75B | 51.53B |
Gross Profit | 28.68B | 9.63B | 50.86B | 49.27B | 43.16B |
EBITDA | 13.90B | 12.72B | 13.29B | 14.25B | 9.73B |
Net Income | 5.76B | 5.24B | 5.64B | 6.96B | 3.75B |
Balance Sheet | |||||
Total Assets | 59.51B | 56.21B | 52.44B | 50.74B | 47.49B |
Cash, Cash Equivalents and Short-Term Investments | 2.02B | 1.02B | 1.00B | 1.55B | 1.91B |
Total Debt | 45.24B | 41.86B | 40.20B | 36.73B | 33.06B |
Total Liabilities | 58.96B | 55.15B | 52.51B | 49.25B | 44.60B |
Stockholders Equity | -2.50B | -1.77B | -2.77B | -933.00M | 572.00M |
Cash Flow | |||||
Free Cash Flow | 5.64B | 4.69B | 4.13B | 5.38B | 6.40B |
Operating Cash Flow | 10.51B | 9.43B | 8.52B | 8.96B | 9.23B |
Investing Cash Flow | -4.93B | -5.32B | -3.39B | -2.64B | -3.39B |
Financing Cash Flow | -4.58B | -4.09B | -5.66B | -6.66B | -4.68B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $15.78B | 23.96 | 4.36% | 0.10% | -0.91% | 27.17% | |
73 Outperform | $10.02B | 9.26 | 18.35% | 0.51% | 9.73% | 51.87% | |
70 Outperform | $10.93B | 14.33 | 260.92% | ― | 5.11% | 14.28% | |
69 Neutral | $82.15B | 15.70 | -230.22% | 0.83% | 6.37% | ― | |
67 Neutral | $13.78B | 9.50 | 41.09% | ― | -1.09% | -43.10% | |
65 Neutral | $10.96B | 22.45 | 25.33% | 0.63% | 11.21% | 30.38% | |
65 Neutral | ¥355.44B | 11.10 | -2.99% | 2.49% | 11.76% | -10.16% |
On July 25, 2025, HCA Healthcare announced its financial results for the second quarter of 2025, reporting a 6.4% increase in revenues to $18.605 billion and a 13.1% rise in net income to $1.653 billion compared to the same period in 2024. The company also declared a quarterly cash dividend of $0.72 per share, to be paid on September 30, 2025. HCA Healthcare raised its 2025 guidance, reflecting strong financial performance and operational improvements, with adjusted EBITDA increasing by 8.4% to $3.849 billion. The company repurchased 7.031 million shares of its common stock and had $5.753 billion remaining under its repurchase authorization as of June 30, 2025.
The most recent analyst rating on (HCA) stock is a Buy with a $425.00 price target. To see the full list of analyst forecasts on HCA Healthcare stock, see the HCA Stock Forecast page.
On July 8, 2025, HCA Healthcare announced the appointment of John W. Chidsey, III to its Board of Directors, effective July 15, 2025, expanding the board from nine to ten members. Chidsey, with a distinguished career including leadership roles at Subway and Burger King, will serve on several key committees, bringing valuable financial and operational expertise to HCA Healthcare. This strategic appointment is expected to bolster the company’s commitment to improving healthcare delivery and patient outcomes.
The most recent analyst rating on (HCA) stock is a Buy with a $425.00 price target. To see the full list of analyst forecasts on HCA Healthcare stock, see the HCA Stock Forecast page.
On June 10, 2025, HCA Inc., a subsidiary of HCA Healthcare, established a commercial paper program to issue up to $4 billion in unsecured notes, guaranteed by HCA Healthcare. The notes, intended for general corporate purposes, will be sold privately in the U.S. commercial paper market and are not registered under the Securities Act of 1933.
The most recent analyst rating on (HCA) stock is a Buy with a $385.00 price target. To see the full list of analyst forecasts on HCA Healthcare stock, see the HCA Stock Forecast page.
On April 24, 2025, HCA Healthcare‘s Board of Directors approved the 2025-2026 compensation program for non-management directors, which includes cash retainers and equity awards. The company also held its Annual Meeting on the same day, where key decisions were made, including the election of directors, approval of amendments to the stock incentive plan, and ratification of Ernst & Young LLP as the accounting firm. Stockholder proposals on golden parachutes and acquisition strategy were not approved.